secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2025-02-21T23:59:59+00:00
Accession:  0000950170-25-024989
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics secures $20M equity purchase agreement, expandable to $40M
------------------------------------------------------------------------

- Equity Purchase Agreement with Square Gate Capital Master Fund for up to $20M initial, up to $40M total.
- Company may sell shares at 98% of lowest daily VWAP over 3-day valuation period; no obligation to sell.
- 36-month commitment period; Investor prohibited from short sales or hedging.
- $150,000 commitment fee paid in common shares; Registration Rights Agreement filed.
- Proceeds to fund clinical development programs and expand R&D activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000095017025024989/0000950170-25-024989-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000095017025024989/hcwb-20250220.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-024989

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer